Protalix BioTherapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDProtalix BioTherapeutics, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is moderate (RS Rating: 62), indicating performance broadly in line with the market. Earnings growth of 6% provides fundamental context to the price action. Investors should exercise caution due to high volatility (65% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $2.08 | +10.52% | ABOVE |
| 50 SMA | $2.08 | +10.55% | ABOVE |
| 100 SMA | $2.35 | -2.14% | BELOW |
| 150 SMA | $2.19 | +4.80% | ABOVE |
| 200 SMA | $2.19 | +4.99% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is PLX in an uptrend right now?
PLX has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is PLX overbought or oversold?
PLX's RSI (14) is 61. The stock is in neutral territory, neither overbought nor oversold.
Is PLX outperforming the market?
PLX has a Relative Strength (RS) Rating of 62 out of 99. PLX is performing about average compared to the market.
Where is PLX in its 52-week range?
PLX is trading at $2.30, which is 72% of its 52-week high ($3.19) and 51% above its 52-week low ($1.36).
How volatile is PLX?
PLX has a Beta of 1.59 and 52-week volatility of 65%. It's more volatile than the S&P 500 - expect bigger swings.